Sage Therapeutics SAGE announced that its board of directors has rejected the unsolicited, non-binding proposal offer from ...

It was a busy week for the biotech sector, with regulatory and pipeline updates. Sage Therapeutics SAGE was in focus after it ...

After receiving and considering an "unsolicited" buyout offer from partner Biogen, Sage Therapeutics is kicking the tires on ...

Sage’s board of directors said that the proposal “significantly undervalues” the company and is not in the best interest of ...

With the prospects for its Alzheimer’s drug aducanumab still up in the air, Biogen has moved to shore up its late-stage pipeline with a $3 billion licensing deal with Sage that adds drugs for ...

Sage Therapeutics has brought a lawsuit against Biogen shortly after receiving an “unsolicited” offer from its neuroscience ...

Biogen’s effort to buy Sage reveals its “desire to expand its pipeline at a discount,” according to analysts from BMO Capital ...

SAGE has experienced a substantial decline in its stock price, down about 80% in the past year, partly due to setbacks in its drug pipeline, including the discontinuation of zuranolone for major ...

Sage Therapeutics, Inc. filed an 8-K report with the Securities and Exchange Commission. The filing disclosed that the Board of Directors of Sage Therapeutics has commenced a strategic review process ...

That was the challenge for Sage Pay, who had a pipeline gap for their payment gateway software and only held 6% market share among retail and hospitality SMEs. Even if their payment gateway wasn’t ...

Meanwhile, Sage reported failed phase 2 trials of dalzanemdor in Alzheimer's, Parkinson's, and Huntington's disease, and ...